-

•

~~

CLAIM	SUPPORT
	Co., St. Louis, MO., USA.
	C. 12, L. 1-3: Alternatively,
	commercially available
	antibodies can be used.
	α -Human β -amyloid 6F/3D was
	obtained
	C. 16, L. 27-33: Recent
	advances in antibody
	engineering technology, as
	well as in the development of
	suitable delivery
	systems make it possible to
	develop functional small
	antibody fragments to serve
	as therapeutic chaperones for
	the treatment of Alzheimer's
	disease as well as other
	human amyloidosis diseases

.

G:\BN\R\ramg\Solomon1R\ClaimSupportChart.DOC

.

- 15 -

PAGE 2/21 * RCVD AT 4/26/2004 5:28:33 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/2 * DNIS:8729306 * CSID: * DURATION (mm-ss):09-04